Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viralym-C for CMV Infections Post-HSCT
NCT02313857Phase 1Completed
- Sponsor
- AlloVir
- Start
- Sep 2015
- Primary completion
- May 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Viralym-C in cytomegalovirus infection (CMV), sponsored by AlloVir. Primary endpoint: Assessment of patients with adverse events after Viralym-C infusion at 42 days. Started Sep 2015; status: completed.
02
Drugs
Viralym-C
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02313857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313857.